References
Silver RJ (2020) The Endocannabinoid System of Animals. 2019 Sep 16;9(9). pii: E686. doi: 10.3390/ani9090686.
Pacher P, et al. "The Endocannabinoid System as an Emerging Target of Pharmacotherapy". Pharmacol Rev. 2006 Sep; 58(3): 389–462. doi: 10.1124/pr.58.3.2
Russo EB. "Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?". Neuro Endocrinol Lett. 2008 Apr;29(2):192-200.
Russo EB. "Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes." Cannabis Cannabinoid Res. 2016 Jul 1;1(1):154-165. doi: 10.1089/can.2016.0009. eCollection 2016.
Bouter Y. et al. "Chronic Psychosocial Stress Causes Increased Anxiety-Like Behavior and Alters Endocannabinoid Levels in the Brain of C57Bl/6J Mice." Cannabis Cannabinoid Res. 2020 Mar; 5(1):51-61.http://doi.org/10.1089/can.2019.0041. eCollection 2019 Nov 13.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605027/
